1 Short and long term mortality and causes of death in HIV/TB patients in Europe. DN Podlekareva, AM Panteleev, D Grint, FA Post, JM Miro, M Bruyand, H Furrer, N Obel, E Girardi, A Vassilenko, MH Losso, A Arenas-Pinto, J Caylá, A Rakhmanova, I Zeltina, AM Werlinrud, JD Lundgren, A Mocroft, O Kirk; the HIV/TB study group.
Eur Respir J. 2014;43(1):166-77. abstract (IF: 7.125)

2 Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. DA Kamara, L Ryom, M Ross, O Kirk, P Reiss, P Morlat, O Moranne, CA Fux, A Mocroft, C Sabin, JD Lundgren, CJ Smith. 
BMC Nephrol. 2014;15(1):51.  abstract (IF: 1.52)

3 Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons in the D:A:D study. L Ryom, A Mocroft, O Kirk, M Ross, P Reiss, CA Fux, P Morlat, O Moranne, C Smith, W El-Sadr, M Law, JD Lundgren et al. for the D:A:D study group. 
AIDS. 2014; 28(2):187-99. abstract (IF: 6.557)

4 Increased incidence of antiretroviral drug discontinuation among patients with viremic HCV coinfection and high hyaluronic acid, a marker of liver fibrosis. D Grint, L Peters, J Rockstroh, S De Wit, VM Mitsura, B Knysz, C Pedersen, O Kirk, JD Lundgren, A Mocroft for EuroSIDA in EuroCoord.  
AIDS. 2014; 28(4):577-87. abstract (IF: 6.557)

5 A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. A Mocroft, L Ryom, P Reiss, H Furrer, A D'Arminio Monforte, J Gatell, S De Wit, M Beniowski, JD Lundgren, O Kirk; EuroSIDA in EuroCOORD.
HIV Med. 2014;15(3):144-52. abstract (IF: 3.454)

6 Hepatitis – a devastating epidemic in Europe. JV Lazarus, KA Fenton.
BMC Infectious Diseases, 2014;14(Suppl 6):S1 abstract (IF: 2.561)

7 Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. JV Lazarus, JD Lundgren, J Casabona. et al.
BMC Infectious Diseases,  2014;14(Suppl 6):S18. abstract (IF: 2.561)

8 Health service delivery models for the provision of antiretroviral therapy in sub-Saharan Africa: a systematic review. JV Lazarus, K Safreed-Harmon, J Nicholson, S Jaffar.
TMIH,  2014;19(10):1198-215 abstract (IF: 2.302)

Journal of Clinical Laboratory Analysis. 2014; 28(2):163-7 abstract (IF: 1.144)

16 Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. FA Post, D Grint, AM Werlinrud, A Panteleev, V Riekstina, EA Malashenkov, A Skrahina, D Duiculescu, D Podlekareva, I Karpov, V Bondarenko, N Chentsova, J Lundgren, A Mocroft, O Kirk, JM Miro; HIV-TB Study Group. 
J Infect. 2014 ;68(3):259-63. abstract (IF: 4.017) 

17 Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. R Aabenhus, JU Jensen, KJ Jørgensen, A Hróbjartsson, L Bjerrum. 
Cochrane Database Syst Rev. 2014 ;11. abstract (IF: 5.939)

18 Novel biomarkers of infection in critically ill cancer patients: certainties and doubts. JU Jensen, JD Lundgren. 
Crit Care Med. 2014;42(12):2632-3. abstract (IF: 6.147)

19 Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
AIDS. 2014 ;28(15):2297-306. abstract (IF: 6.557)

20 Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
AIDS. 2014 ;28(9):1351-6. abstract (IF: 6.557)

21 Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. FN Engsig, R Zangerle, O Katsarou, F Dabis, P Reiss, J Gill, K Porter, C Sabin, A Riordan, G Fätkenheuer, F Gutiérrez, F Raffi, O Kirk, M Mary-Krause, C Stephan, PG de Olalla, J Guest, H Samji, A Castagna, A d'Arminio Monforte, A Skaletz-Rorowski, J Ramos, G Lapadula, C Mussini, L Force, L Meyer, F Lampe, F Boufassa, HC Bucher, S De Wit, GA Burkholder, R Teira, AC Justice, TR Sterling, H Crane, J Gerstoft, J Grarup, M May, G Chêne, SM Ingle, J Sterne, N Obel; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
Clin Infect Dis. 2014;58(9):1312-21. abstract (IF: 9.416)

22 Incorrect inclusion of individual studies and methodological flaws in systematic review and meta-analysis. R Aabenhus, JU Jensen, JW Cals. 
Br J Gen Pract. 2014; 64(622):221-2. abstract (IF: 2.356)

23 Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier cART will alter this risk.  AH Borges, R Dubrow, MJ Silverberg. 
Current Opinion in HIV and AIDS. 2014; 9(1):34-40. abstract (IF: 4.392)

24 Factors associated with D-dimer levels in HIV-infected individuals. AH Borges, JL O’Connor, AN Phillips, JV Baker, MJ Vjecha, MH Losso, H Klinker, G Lopardo, I Williams, JD Lundgren; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. 
PLoS One. 2014 ;9(3):e90978. abstract (IF: 3.534)

25 Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. AD Nordell, M McKenna, ÁH Borges, D Duprez, J Neuhaus, JD Neaton; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. 
J Am Heart Assoc. 2014 ;3(3):e000844. abstract (IF: 2.882)
  
26 Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. ÁH Borges, JI Weitz, G Collins, JV Baker, Y Lévy, RT Davey Jr, AN Phillips, JD Neaton, JD Lundgren, SG Deeks; INSIGHT SILCAAT Scientific Committee. 
AIDS. 2014 ;28(12):1791-6.  abstract (IF: 6.557)

27 Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. ÁH Borges, JD Lundgren, A Ridolfo, C Katlama, F Antunes, A Grzeszczuk, A Blaxhult,  VM Mitsura, M Doroana, M Battegay, P Gargalianos, A Mocroft; on behalf of EuroSIDA in EuroCOORD. 
AIDS. 2014  28(17) 2565-2571. abstract (IF: 6.557)

28 Trends in underlying causes of death in people with HIV from 1999-2011 (D:A:D): a multicohort collaboration . CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, S De Wit, M Law, W el Sadr, O Kirk, N Friis-Moller, A d’Arminio Monforte, AN Phillips, CA Sabin, JD Lundgren, D:A:D Study Group.
Lancet. 2014 ;384(9939):241-8. abstract (IF: 39.207)

29 HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. L Peters, A Mocroft, J Lundgren, D Grint, O Kirk, J Rockstroh. 
BMC Infect Dis. 2014;14 Suppl 6:S13. abstract (IF: 2.561)

30 Increased risk of cardiovascular disease (CVD) with age in HIV positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.  K Petoumenos, P Reiss, L Ryom, M Rickenbach, C Sabin, W El-Sadr, A d'Arminio Monforte, A Phillips, S De Wit, O Kirk, F Dabis, C Pradier, J Lundgren, M Law; D:A:D Study Group. 
HIV Med. 2014;15(10):595-603. abstract (IF: 3.454)

31 Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. L Shepherd, JC Souberbielle, JP Bastard, S Fellahi, J Capeau, J Reekie, P Reiss, A Blaxhult, M Bickel, C Leen, O Kirk, JD Lundgren, A Mocroft, JP Viard, On behalf of EuroSIDA in EuroCOORD. 
J Infect Dis. 2014 ;210(2):234-43. abstract (IF: 5.778)

32 Deteriorating renal function and clinical outcomes in HIV-positive persons. A Mocroft, L Ryom, J Begovac, Ad Monforte, A Vassilenko, J Gatell, E Florence, V Ormaasen, O Kirk, JD Lundgren, EuroSIDA in EuroCOORD. 
AIDS. 2014 ;28(5):727-37. abstract (IF: 6.557)

33 High rate of hepatitic C virus (HCV) recurrence in HIV infected individuals with spontaneous HCV-RNA clearance. L Peters, A Mocroft, V Soriano, J Rockstroh, N Kirkby, P Reiss, C Katlama, N Zakharova, R Flisiak, J Lundgren. 
HIVMed. 2014 ; 15(10):615-20. abstract (IF: 3.454)

34 A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, AN Phillips, S De Wit, M Ristola, JD Lundgren, J Grarup, O Kirk, EuroSIDA in EuroCOORD. 
Infection. 2014 Aug;42(4):757-62. abstract (IF: 2.864)

35 Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. LC Young, MP Roediger, G Grandits, J Baker, C Somboonwit, I Williams, JD Lundgren, JD Neaton, EZ Soliman. 

Biomark Med. 2014 ;8(9):1073-83. abstract (IF: 2.858)

36 Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. A Phillips, V Cambiano, F Nakagawa, T Magubu, A Miners, D Ford, D Pillay, A De Luca, J Lundgren, P Revill. 
PLoS One. 2014 ;9(10):e109148. abstract (IF: 3.534)

37 Potential future impact of a partially effective HIV vaccine in a southern African setting. AN Phillips, V Cambiano, F Nakagawa, D Ford, JD Lundgren, E Roset-Bahmanyar, F Roman, R Van Effelterre.

PLoS One. 2014 ;9(9):e107214. abstract (IF: 3.534)

38 Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, JA Hontelez, S Humair, CC Kerr, DJ Klein, S Mishra, KM Mitchell, BE Nichols, P Vickerman, R Bakker, T Bärnighausen, A Bershteyn, DE Bloom, MC Boily, ST Chang, T Cohen, PJ Dodd, C Fraser, C Gopalappa, J Lundgren, NK Martin, E Mikkelsen, E Mountain, QD Pham, M Pickles, A Phillips, L Platt, C Pretorius, HJ Prudden, JA Salomon, DA van de Vijver, SJ de Vlas, BG Wagner, RG White, DP Wilson, L Zhang, J Blandford, G Meyer-Rath, M Remme, P Revill, N Sangrujee, F Terris-Prestholt, M Doherty, N Shaffer, PJ Easterbrook, G Hirnschall, TB Hallett. 
Lancet Global Health. 2014 ;2(1):e23-34. abstract

39 Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies. R Lynfield, R Davey, DE Dwyer, MH Losso, D Wentworth, A Cozzi-Lepri, K Herman-Lamin, G Cholewinska, D David, S Kuetter, Z Ternesgen, TM Uyeki, HC Lane, J Lundgren, JD Neaton: INSIGHT Influenza Study Group. 
PLoS One. 2014 ;9(7):e101785. abstract (IF: 3.534)

40 Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. L Peters, J Neuhaus, D Duprez, JD Neaton, R Tracy, MB Klein, A Mocroft, J Rockstroh, G Dore, JD Lundgren; INSIGHT SMART Study Group. 
J Clin Virol. 2013; 60(3):295-300. abstract (IF: 3.466)

41 Update on HIV in Western Europe. F Nakagawa, AN Phillips, JD Lundgren.
Curr HIV/AIDS Rep. 2014 ;11(2):177-85. abstract

42 Antiretroviral dose reduction: good for patients and rollout. JD Lundgren, A Phillips.
Lancet. 2014 ;383(9927):1442-3. abstract (IF: 39.207)

43 Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. A Zoufaly, A Cozzi-Lepri, J Reekie, O Kirk, J Lundgren, P Reiss, D Jevtovic, L Machala, R Zangerle, A Mocroft, J Van Lunzen; EuroSIDA in EuroCoord. 
PLoS One. 2014 ;9(1):e87160. abstract (IF: 3.534)

44 Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. V Cambiano, S Bertagnolio, MR Jordan, D Pillay, JH Perriëns, F Venter, J Lundgren, A Phillips.
AIDS. 2014 ;28 Suppl 1:S15-23. abstract (IF: 6.557)

45 Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. FZ Dawood, MP Roediger, G Grandits, D Miller, M Fisher, ZM Zhang, S Hodder, JF Hoy, JD Lundgren, JD Neaton, EZ Soliman; INSIGHT SMART Study Group. 
J Electrocardiol. 2014;47(2):264-71. abstract (IF: 1.363)

46 Antiretroviral therapy recommendations for the global community: aspiration versus reality. AN Phillips, P Munderi, PA Revill, WM El-Sadr, JD Lundgren. AIDS. 2014 24;28(7):939-41. abstract (IF: 6.557)

47 Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. L Ryom, A Mocroft, JD Lundgren.
Curr Opin HIV AIDS. 2014 ;9(1):41-7. abstract (IF: 4.392)

48 People with HIV are at increased risk of acute myocardial infarction. JD Lundgren. 
Evid Based Nurs. 2014 ;17(2):43-4. abstract 

49 Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS142 randomised non-inferiority trial. F Raffi, AG Babiker, L Richert, JM Molina, EC George, A Antinori, JR Arribas, J Grarup, F Hudson, C Schwimmer, J Saillard, C Wallet, PO Jansson, C Allavena, R Van Leeuwen, JF Delfraissy, S Vella, G Chêne, A Pozniak; NEAT001/ANRS143 Study Group.
Lancet. 2014 ;384(9958):1942-51. abstract (IF: 39.207)